CorMedix Inc. CRMD disclosed that its Professor of Medicine and Director of Nephrology, would deliver a oral presentation. The title was "A Novel Taurolidine Containing Catheter Lock Solution CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study."
CorMedix said that the data would be presented at the 53rd ERA-EDTA congress that is being held in May in Austria between 21 and 24.
The company's CEO, Randy Milby, commented, "The Neutrolin Usage Monitoring Program data has produced valuable insights from real world use in the EU, where Neutrolin is approved for the reduction of catheter-related blood stream infections and thrombosis."
He said further, "We've shared some general data from the program, which has demonstrated positive results consistent with our trials that appear to validate Neutrolin's clinical utility. We look forward to presenting a more formal analysis to this esteemed gathering of nephrologists."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.